STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Survodutide

Also known as

BI 456906 · BI456906 · BI-456906 · glucagon/GLP-1 dual agonist · GCGR/GLP-1R dual agonist · Zealand/Boehringer dual agonist

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic Subcutaneous Metabolic / GLP-1 class

Systemic — once-weekly glucagon/GLP-1 dual agonist for whole-body appetite, weight, energy-expenditure, and hepatic fat effects.

What people say An investigational once-weekly dual glucagon/GLP-1 receptor agonist studied for obesity and liver disease. It is not an approved consumer drug. Doses people talk about
Phase 2 obesity targets0.6, 2.4, 3.6, or 4.8 mg once weekly

Four randomized target arms after multi-week escalation in a 46-week study.

Phase 2 MASH targets2.4, 4.8, or 6.0 mg once weekly

Three target arms across escalation and maintenance; not interchangeable with obesity-arm design.

Phase 3 obesity maintenance3.6 or 6.0 mg once weekly

SYNCHRONIZE-1 maintenance targets after titration and alongside lifestyle counseling.

Amounts preserve study arms and cadence. The full notes retain starting and escalation examples, tolerance holds and unverified-product cautions.

Half-life & effect duration

Half-life in the body
  • Human studyOver 100 hours
  • Secondary estimatesAbout 109–115 hours, or 6–7 days
Felt duration people report
  • One blinded trial accountLong-term weight change, but no felt difference after stopping
  • After one doseNo consistent survodutide-only duration reported
Timing context & sources
How it may feel Trial tables emphasize GI effects and weight/liver endpoints. Direct self-reports are thin; one blinded participant reported large weight loss but could not tell a difference after stopping, and assignment was never confirmed.
Cycles people discuss Clinical studies use long, titrated weekly treatment over roughly 46–76 weeks, not short bodybuilding cycles. Structured off-drug evidence is sparse. Timing Study schedules use once-weekly SubQ dosing with multi-week titration and tolerance holds. Maintenance targets and 46–76-week windows are study designs, not a do-it-yourself escalation or short cycle. Stacks Pivotal programs study survodutide against placebo with lifestyle counseling. Forum comparisons and isolated stacked reports do not establish concurrent multi-incretin use. Watch for GI class effects (dominant): Nausea, vomiting, diarrhea, constipation, decreased appetite — main AE cluster across Phase 2 and Phase 3, worse during dose escalation.
Related
SemaglutideTirzepatideRetatrutideCagrilintide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

The phase 1 paper reports a dose-independent terminal plasma half-life of more than 100 hours.

Single- and multiple-rising-dose studies used subcutaneous BI 456906 in healthy men and adults with overweight or obesity; the long terminal phase supports weekly development.

The paper gives a lower-bound phrase rather than one exact universal value. Population, dose and repeated-dose context must not be collapsed into a six-day meme.

Felt duration people report

No dependable dose-by-dose felt-duration clock is established.

A blinded trial participant reported long-term weight change and later said they could not tell a difference after stopping. Separate stacked reports describe short trials but cannot isolate survodutide.

Blinded assignment was unconfirmed; self-reports are sparse, uncontrolled and sometimes combine tirzepatide. Weight trajectories are not proof of how long one injection is felt.

  • SYNCHRONIZE-1 participant thread and same-author follow-up (opens in a new tab)Original February 2024 first-injection post and the same author’s September 2025 update reporting 231-to-179-lb change, later 180–185-lb fluctuation, final June injection and no felt difference off drug.Blinded assignment remained only a probability, not confirmed active drug; uncontrolled weight history and no verified records.
  • Survodutide and tirzepatide discussion (opens in a new tab)Thread body and replies describing brief, staggered co-use, reported amounts, weight change and energy impressions from multiple authors.Unverified products, stacked exposure, few weeks of follow-up and self-selected posters; cannot establish efficacy, safety or an endorsed schedule.

Other context in this card

What people say 17

  • Appetite (user language): Classic incretin-style quieter hunger, early fullness, smaller meals once titration is tolerated — main “feel” people expect from the class. forum
  • SYNCHRONIZE-1 Phase 3 weight (76 wk, no T2D): Treatment-regimen estimand mean loss ~−12.2% at 3.6 mg and ~−13.0% at 6.0 mg vs ~−5.4% placebo. trial
  • Efficacy estimand (full adherence model): Mean loss reached ~−15.3% (3.6 mg) and ~−16.6% (6.0 mg) vs ~−3.2% placebo — the mid-teens headline often quoted in press. trial
  • Responder cuts (SYNCHRONIZE-1): Roughly ~72–73% on drug hit ≥5% loss vs ~46% placebo; ~28.5% on 6.0 mg hit ≥20% loss vs ~6.6% placebo (coverage summaries). trial
  • Phase 2 obesity (46 wk dose-finding): Mean loss −6.2% (0.6 mg), −12.5% (2.4 mg), −13.2% (3.6 mg), −14.9% (4.8 mg) vs −2.8% placebo (mITT). trial
  • Phase 2 completer headline: Participants who reached and stayed on 4.8 mg often cited at ~18.7% mean weight loss at 46 weeks — the “nearly 19%” figure in early press. trial
  • Phase 2 responder rates (4.8 mg): ~83% ≥5%, ~69% ≥10%, ~55% ≥15% body-weight loss at 46 weeks vs much lower placebo rates. trial
  • MASH Phase 2 (NEJM, 48 wk biopsy): Improvement in MASH with no fibrosis worsening: 47% (2.4 mg), 62% (4.8 mg), 43% (6.0 mg) vs 14% placebo — 4.8 mg peak often highlighted. trial
  • Liver fat Phase 2 (MRI-PDFF ≥30% drop): ~63% (2.4 mg), ~67% (4.8 mg), ~57% (6.0 mg) vs ~14% placebo. trial
  • Fibrosis Phase 2 (≥1 stage improvement): ~34–36% on survodutide arms vs ~22% placebo; F2/F3 subgroup fibrosis-without-worsening-MASH figures (e.g. ~64.5% in some analyses) widely cited in liver-watch coverage. trial
  • SYNCHRONIZE-MASLD Phase 3 (48 wk): ≥30% relative liver-fat reduction by MRI-PDFF in ~84.2% on survodutide (titrated toward 6.0 mg) vs ~24.3% placebo (efficacy estimand). trial
  • Liver-fat normalization (MASLD Phase 3): ~61.0% reached LFC <5% vs ~5.7% placebo; ≥70% LFC drop in ~55.5% vs ~2.9% placebo in coverage summaries. trial
  • Weight in MASLD Phase 3: Mean ~−12.2% with survodutide vs ~−1.0% placebo (efficacy estimand) over 48 weeks. trial
  • Cardiometabolic secondaries: Waist, BP, lipids, and liver enzymes improved in various program summaries alongside weight/liver fat — not a pure scale-only story. trial
  • Glycemic note: Dual design aims for glucagon-driven burn without runaway hyperglycemia; non-diabetic obesity tables show modest glucose shifts; T2D-specific HbA1c work exists in earlier programs / SYNCHRONIZE-2. trial
  • Pipeline status: FDA Breakthrough Therapy (and related Fast Track / EMA PRIME style designations discussed) for MASH with fibrosis in 2024; obesity + MASH Phase 3 still the access path, not retail pens. trial
  • Body-comp imaging (SYNCHRONIZE-1 MRI substudy): At 6.0 mg, visceral fat ~−34.0% and liver fat ~−63.1% vs ~−11.8% and ~−24.5% placebo; fat-tissue loss preferred over lean in sponsor framing. trial

Doses people talk about 12

  • Do not jump: Community and trial culture both treat “start at 3.6–6.0 mg” as outside studied practice — high early GI risk. forum
  • Research-chem caveats: Unlabeled “survodutide” vials (if offered) lack identity/potency proof; trial mg ≠ assumed vial content; no validated public mcg conversion culture like older research peptides. forum
  • Missed dose (class talk): Same-weekday habit preferred; if near next dose day, skip rather than double — extrapolated from weekly incretin practice, not a unique approved label. forum
  • Framing: Trial and publicly discussed research ranges only — not medical advice, not a DIY prescription, not gray-market endorsement. forum
  • Route & cadence: Once-weekly subcutaneous injection is the clinical default across obesity, MASH, and MASLD programs — not daily micro-splits in trials. trial
  • Phase 2 obesity target arms: 0.6 mg, 2.4 mg, 3.6 mg, and 4.8 mg once weekly after multi-week escalation (46-week study). trial
  • Phase 2 MASH arms: 2.4 mg, 4.8 mg, and 6.0 mg once weekly vs placebo over ~48 weeks (24-wk escalate + 24-wk maintain). trial
  • Phase 3 obesity targets (SYNCHRONIZE-1): Once-weekly titration up to maintenance 3.6 mg or 6.0 mg over 76 weeks, plus diet/activity counseling. trial
  • Phase 3 MASLD target: Weekly titration toward 6.0 mg (lower intermediate doses such as 2.4–4.8 mg discussed as allowed when higher not tolerated). trial
  • Common start dose in protocols: ~0.3 mg once weekly is the widely cited clinical starting step before stepwise increases. trial
  • Example Phase 2–style 2-week ladder (research discussion charts): Weeks 1–2: 0.3 mg → 3–4: 0.9 mg → 5–6: 1.8 mg → 7–8: 2.7 mg → 9–10: 3.6 mg → then toward 4.8 mg (and in MASH/Phase 3, up toward 6.0 mg) — exact sponsor Phase 3 step table not always fully public. trial
  • Phase 3 titration philosophy: Slower ~4-week intervals (vs ~2-week Phase 2 rapid ramps) intended to cut GI dropouts; flexible hold/reduce rules built into designs. trial

How it may feel 8

  • Months 3–6 and later: “Appetite quieting” is the dominant dual-agonist discussion theme, but direct survodutide logs are sparse. One blinded SYNCHRONIZE-1 participant later reported weight falling from 231 to 179 lb, then fluctuating around 180–185 after a final June injection; the same author said they could not feel a difference off drug. Assignment remained unconfirmed, so the chronology cannot establish causation. anecdote
  • If GI is rough: Trial protocols allowed dose holds/reductions; community class advice is “hold step, don’t jump to 6 mg.” forum
  • Weeks 1–4: Slow low-dose start (trial charts often open at 0.3 mg weekly); nausea, early satiety, constipation or loose stools commonly appear during first steps. trial
  • Weeks 4–12: Weight usually begins measurable separation from placebo; GI events and dropouts cluster during escalation, not after long stable maintenance. trial
  • Phase 2 ramp context: Obesity dose-finding used ~20 weeks escalation + ~26 weeks maintenance (46-week total); MASH used ~24-week rapid escalation (often every 2 weeks) + 24-week maintenance. trial
  • ~Week 48: MASLD/MASH programs focus MRI-PDFF, enzymes, biopsy, and weight co-endpoints more than energy or mood stories. trial
  • ~76 weeks (SYNCHRONIZE-1): Primary obesity Phase 3 window; plateau vs further loss depends on dose, adherence, and lifestyle counseling in trial design. trial
  • Each step-up: GI often spikes then settles if the step is held — same pattern as other weekly incretins; Phase 3 slowed ramps vs Phase 2 partly for this. trial

Cycles people discuss 6

  • Breaks / time off: Off-drug talk mirrors other incretins (regain risk, GI “reset,” re-titrate if restart); structured survodutide-specific off-cycle data are sparse. forum
  • Switching narratives: Forum comparisons usually sequence agents (sema → tirz → reta / dual watch-list) rather than concurrent multi-agonist stacks. forum
  • Clinical model: Chronic once-weekly therapy measured in many months (46–76+ weeks), not short bodybuilding “blast/cruise” cycles. trial
  • Evidence windows: ~46 wk Phase 2 obesity; ~48 wk MASH / MASLD; ~76 wk SYNCHRONIZE-1 obesity; CVOT and longer MASH (e.g. LIVERAGE-class) programs extend further. trial
  • Titration is the early “cycle”: Most failures to reach studied maintenance doses happen during escalation — early quit ≠ studied effect. trial
  • Maintenance: Built for ongoing weekly use at target (3.6 or 6.0 mg in Phase 3 obesity; 2.4–6.0 mg bands in liver work), not planned on/off bulk seasons. trial

Timing 8

  • Injection-day habit: Same weekday, consistent time preferred over meal-locked timing in community practice. forum
  • Human plasma half-life: In the inspected phase 1 paper, the dose-independent terminal half-life was reported as more than 100 hours after subcutaneous dosing. That supports weekly development but does not establish an exact six-day value for every population. trial
  • Secondary cites: Some research summaries list ~109–115 hours (~4.5–4.8 days) or ~6–7 days; treat single-number memes carefully and prefer primary PK papers. trial
  • Why long-acting: High albumin binding via C18 fatty-diacid modification slows clearance vs native glucagon/GLP-1 minutes-scale half-lives. trial
  • Tmax / absorption: Peak concentrations generally delayed after SC injection (multi-hour to multi-day class pattern; secondary sources often cite ~1–3 days or ~60–96 hours ranges). trial
  • Steady state: Full weekly steady-state exposure lags several weeks of continuous dosing; effect at target dose is not “day-1 max.” trial
  • Downstream levers: GLP-1 → appetite / gastric emptying / glucose-dependent insulin; glucagon → hepatic lipid oxidation, energy-expenditure, and liver-fat narratives beyond scale weight. trial
  • Feel vs imaging: Appetite change can appear early; visceral/liver-fat and percent-weight endpoints need multi-month windows. trial

More on what it is 8

  • Why people search it: Next-wave dual-agonist fat-loss + unusually strong MASH/MASLD liver-fat trial story; Phase 3 SYNCHRONIZE readouts put it on the obesity-pipeline radar next to reta / CagriSema. forum
  • DIY honesty: Far fewer personal research-chem logs than sema/tirz/reta; most “dosing talk” is trial titration charts, not thick forum n=1 libraries. forum
  • What it is: Investigational long-acting dual glucagon receptor (GCGR) + GLP-1 receptor agonist peptide; development code BI 456906. trial
  • Origin: Originated at Zealand Pharma; licensed to Boehringer Ingelheim for global development and commercialization. trial
  • Structure (plain): ~29-amino-acid peptide related to glucagon/oxyntomodulin backbone, with amino-acid substitutions for dual receptor activity and a C18 fatty-diacid side chain for albumin binding / once-weekly exposure. trial
  • Mechanism (plain): GLP-1 arm reduces appetite and slows gastric emptying; glucagon arm is framed as raising energy expenditure / hepatic fat oxidation — dual “eat less + burn/liver-clear” pitch. trial
  • Evidence level: Multiple Phase 2 RCTs (obesity, MASH, cirrhosis PK) plus Phase 3 SYNCHRONIZE-1 (obesity) and SYNCHRONIZE-MASLD (liver fat) public results; still not an approved consumer drug. trial
  • Not the same as: Not semaglutide (GLP-1 only), not tirzepatide (GIP/GLP-1), not retatrutide (GIP/GLP-1/glucagon triple), not mazdutide/pemvidutide/cotadutide (other duals with different dose cultures). trial

Stacks 7

  • Forum “stacks” = comparisons: Usually sequential or hypothetical compare to semaglutide / tirzepatide / retatrutide / mazdutide / pemvidutide / CagriSema — not concurrent DIY multi-incretin cocktails. forum
  • Avoid dual-incretin stacking: Running survodutide with another GLP-1-pathway agent treated as redundant GI load + unknown safety; not a researched stack. forum
  • Muscle preservation supports: Higher protein + resistance training commonly recommended whenever large fat loss is expected. forum
  • GI supports (class): Smaller meals, slower eating, hydration/electrolytes, fiber management, clinician-directed anti-nausea tactics — more discussed than exotic peptide add-ons. forum
  • Injury peptides: Occasional co-mention of BPC-157/TB-500 in general peptide culture is unrelated to metabolic endpoints — attribution noise. forum
  • Lifestyle co-intervention: Trials pair drug with diet counseling (often reduced-calorie guidance) and physical-activity advice — not drug-in-isolation designs. trial
  • Monotherapy in pivots: Phase 3 obesity/MASLD programs study survodutide vs placebo, not multi-agonist combos. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 17

  • Gallbladder / rapid loss: Class watch with fast weight loss (biliary events); check trial/class warnings rather than assume zero risk. forum
  • Injection site: Local reactions possible; rotate sites — class practice. forum
  • Source / counterfeit risk: Unapproved vials may be mislabeled, underfilled, contaminated, or not survodutide at all; trial safety tables do not cover gray-market product. forum
  • Borrowed class cautions: Thyroid C-cell / MTC–MEN2-style GLP-1 boxed-warning discourse is often imported in community talk; treat as class caution language, not a finished survodutide consumer label. forum
  • GI class effects (dominant): Nausea, vomiting, diarrhea, constipation, decreased appetite — main AE cluster across Phase 2 and Phase 3, worse during dose escalation. trial
  • Phase 2 obesity GI rates: Any GI disorder ~75% on survodutide vs ~42% placebo; treatment-emergent AEs overall ~91% vs ~75% placebo. trial
  • Phase 2 MASH GI rates (pooled drug vs placebo): Nausea ~66% vs ~23%; diarrhea ~49% vs ~23%; vomiting ~41% vs ~4%. trial
  • Discontinuation — Phase 2 obesity: AE-related stop ~24.6% survodutide vs ~3.9% placebo; mostly GI, concentrated in escalation. trial
  • Discontinuation — Phase 2 MASH: AE discontinuation ~20% across survodutide doses vs ~3% placebo (large share GI). trial
  • Discontinuation — SYNCHRONIZE-1 Phase 3: GI-related discontinuation roughly ~17.8% (3.6 mg) and ~20.2% (6.0 mg) vs ~2.9% placebo — still a competitive concern vs some approved incretins. trial
  • Discontinuation — SYNCHRONIZE-MASLD: Treatment discontinuation from AEs ~19.9% survodutide vs ~4.3% placebo; GI events mainly mild–moderate and escalation-timed. trial
  • SAE note: Serious AE rates not consistently higher than placebo in several tables (sometimes lower) — GI intolerance drives dropouts more than rare severe signals in published summaries. trial
  • Lean mass: Some absolute lean loss can accompany large total loss; protein + lifting are usual mitigation talk; imaging work emphasizes preferential fat (incl. visceral/hepatic) loss. trial
  • Cirrhosis PK context: Dedicated work in compensated/decompensated cirrhosis cohorts found generally manageable GI TEAEs and no simple PK-driven dose cut rule in published conclusions — advanced liver self-experimentation remains out of bounds. trial
  • Hypoglycemia / glucose: Dual design is not framed as pure insulin secretagogue; still caution if co-using other glucose-lowering agents in T2D contexts. trial
  • Regulatory honesty: Investigational — not FDA/EMA approved as a marketed obesity or MASH drug at research cutoff; Breakthrough designation ≠ available therapy. trial
  • Not risk-free: Strong weight and liver signals sit next to high GI burden, multi-month commitment, and incomplete long-term real-world safety outside trials. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →